$NTLA
3 articles on $NTLA
- FDABullish
What the Round Table Is Predicting in Biotech Markets
Seventeen FDA decisions fall due between 30 October 2026 and 29 June 2027, and KXCO's Round Table has called every one. Its model portfolio holds the thirteen Nasdaq companies behind them, led by BridgeBio, Cogent Biosciences and Praxis, and was signed with ML-DSA-87 and anchored on chain before the FDA acts. The first test is Inovio's INO-3107 on 30 October.
Shayne Heffernan5 min - $BBIOBullish
The FDA Calendar to April 2027: 5 Biotech Stocks From the KXCO Biotech Ontology
The KXCO Biotech Ontology's board carries 11 pending FDA filings, due by 23 April 2027. Ranked on approval standing, the top five are BridgeBio's BBP-418, Cogent's bezuclastinib, Belite Bio's tinlarebant, Novo Nordisk's CagriSema and BioMarin's vosoritide. Ranked on consensus upside, they are Cullinan, Savara, Intellia, Mineralys and Pharvaris. No name is on both lists. This report covers BridgeBio, Cogent, Mineralys, Pharvaris and Savara.
Shayne Heffernan23 min - $RAREBullish
The Hottest Biotechs of 2026
Twenty FDA approval actions so far in 2026, eight of them inside a sixteen-day window in August. A first-in-class RAS inhibitor that doubled survival in pancreatic cancer, an oral GLP-1 cleared in fifty days, a first gene therapy for GSDIa, and seven AI platforms with nine assets in humans and nothing yet approved.
Shayne Heffernan45 min